Gelstat appoints president
This article was originally published in The Tan Sheet
Executive SummaryWilliam Colucci is appointed president, a newly created position, the OTC marketer announces Sept. 5. Colucci's knowledge and relationship in the financial community will play a key role in the firm's long-term strategies, the company notes. "We expect that Bill's experience analyzing business processes and improving operation performance coupled with [marketing efforts] will dramatically accelerate our pace to return GelStat to profitability," CEO and Chairman James LaFlamme says in a statement. The firm markets GelStat brand OTC treatments for pain and inflammation in retail chains, independent retailers, pharmacies and direct-to-consumer channels...
You may also be interested in...
Brands unfairly maligned by powerful influencers, strictly on behalf of paying competitors, could have occasion to broach the subject with the US Federal Trade Commission, which seeks comment on its “Endorsement Guides” in an increasingly complex and competitive, digitized advertising environment.
At least one FTC commissioner seems convinced that the agency’s Enforcement Guides are ripe for an update to address unscrupulous influencer marketing practices. Democrat Rohit Chopra proposes their codification into formal rules that would make violators liable for civil penalties and damages under FTC Act provisions.
The US agency has suspended all routine surveillance inspections in China through the end of March because of coronavirus fears, commissioner Stephen Hahn announced late on 14 February. Despite expecting medical product shortages, Hahn said the agency is being proactive: “We are not waiting for drug and device manufacturers to report shortages to us” before acting. The timing of Hahn’s statement – at 6 p.m. EST on a Friday, at the beginning of a three-day US holiday weekend – suggests he isn’t particularly excited to share the information.